Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (January 2011)

34 slides from Paratek Pharmaceuticals's investor presentation, Jan 26, 2011

  1. Slide 1: Transcept Pharmaceuticals - January 2011

    Exhibit 99.1 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience January 2011

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Examples of such statements include our expectat

  3. Slide 3: Transcept: preparing for Intermezzo commercialization

    Transcept: preparing for Intermezzo® commercialization Therapeutic focus Neuroscience / psychiatry Large markets, Intermezzo®: middle of the night awakenings unmet needs Setrodon™: treatment resistant OCD Commercial U.S. primary care partnership: Purdue Pharma platform Co-promote option 1 yr post In

  4. Slide 4: Intermezzo

    * * * * * * * * * * * * Intermezzo® (zolpidem tartrate sublingual tablet) Proposed indication statement: Intermezzo® is indicated for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep

  5. Slide 5: Middle of the night awakening: a major unmet medical need in insomnia

    Middle of the night (MOTN) awakening: A major unmet medical need in the insomnia category Large U.S. insomnia market – $2.1 billion (ex-factory)(1) – 78 million new and refill prescriptions(2) Insomnia is an under-treated condition – 11 million patients receive Rx(3) – 4x to 6x more are not diagnose

  6. Slide 6: No product currently indicated for prn treatment at middle of the night awakening

    No product currently indicated for prn treatment at the time of a middle of the night awakening MOTN awakenings typically do not occur every night 7-8 hr sleep aids (Ambien ®, Ambien CR®, Lunesta®) require bedtime prophylactic dosing to prevent awakenings An ideal therapeutic would: – Be used only a

  7. Slide 7: Intermezzo: anticipated first sleep aid for use in the middle of the night

    Intermezzo ®: anticipated to be the first sleep aid for use in the middle of the night at the time of awakening Sublingual tablet dissolves in ~ 2 minutes Novel formulation pH drives zolpidem base, rapidly absorbed Low dose 72% lower dose than Ambien CR® Sleep lab, objective data: 14 minute sleep Fa

  8. Slide 8: Intermezzo 3.5 mg delivered greater early zolpidem bioavailability than higher Ambien dose

    Intermezzo ® 3.5 mg delivered greater early zolpidem bioavailability than a ~3x higher Ambien ® dose 8

  9. Slide 9: Intermezzo commercial opportunity

    * * * * * * * * * * Intermezzo® commercial opportunity

  10. Slide 10: Estimating the MOTN market size at branded prices

    Estimating the MOTN market size at branded prices Ohayon, et al., Nocturnal Awakenings in the American 3 235 M U.S. adults x Ohayon General Population: Prevalence and Consequences 1 MOTN sufferers at least 3x week 35.5% = 1 …with difficulty returning to sleep 43.0% = 1 …without difficulty initiating

  11. Slide 11: Commercialization partnership with Purdue Pharma

    Commercialization partnership with Purdue Pharma Leading pain therapeutic franchise 2009 rev: >$2.5 billion Branded products include: OxyContin®, MSContin®, Dilaudid®, Butrans® Sales force of >500 field reps calling on primary care physicians and high prescribing specialists High value pain prescrib

  12. Slide 12: Commercialization agreement: key Transcept benefits

    Commercialization agreement: key Transcept benefits Co-promote option: foundation for a commercial future – Transcept option: co-promote to psychiatrists as early as the first anniversary after Purdue launch Milestone payments – Upfront license fee: $25M received August 2009 – FDA approval milestone

  13. Slide 13: Partnership structure enables significant Transcept marketing efficiency

    Intermezzo ® partnership structure enables significant Transcept marketing efficiency Purdue responsibilities – U.S. product launch – Primary care sales and marketing activities – Managed care and formulary placement – Manufacturing and distribution – Post marketing studies, if required – Book reven

  14. Slide 14: Favorable market conditions for Intermezzo launch

    Favorable market conditions for Intermezzo ® launch Intermezzo ®: anticipated to be the first strongly differentiated insomnia treatment strategy since launch of Ambien ® in 1993 Continuing decline in sales presentations to physicians in insomnia segment Significantly reduced DTC spending 14

  15. Slide 15: Managed markets research: broad reimbursement coverage expected

    Intermezzo ® managed markets research: broad reimbursement coverage expected Research conducted with Pharmacy and Medical Directors from health plans covering 170M lives Statement of unmet medical need generally well accepted by payers – Unique insomnia indication – Low dose used less often – Delive

  16. Slide 16: Intermezzo NDA resubmission

    * * * * * * * * * * Intermezzo® NDA resubmission

  17. Slide 17: FDA Complete Response Letter (October 2009) and subsequent discussions

    FDA Complete Response Letter (October 2009) and subsequent discussions FDA indicated Transcept has submitted substantial evidence of effectiveness for Intermezzo ® in its intended indication FDA recognized that the Intermezzo ® Phase 3 data did not indicate significant next morning residual effects

  18. Slide 18: Intermezzo NDA resubmitted Jan 2011: 6 month review cycle anticipated

    Intermezzo ® NDA resubmitted Jan 2011: 6 month review cycle anticipated Driving study primary statistical analysis: no significant next morning effect when dosed per proposed label Comparative analysis vs. previous driving study data: even when dosed off label (< 4hrs prior to driving), Intermezzo®

  19. Slide 19: Redesigned unit dose packaging for NDA resubmission

    Redesigned unit dose packaging for NDA resubmission 19

  20. Slide 20: Intermezzo highway driving study overview

    Intermezzo ® highway driving study overview Approximately 40 healthy adult volunteers Highway driving over a one-hour period Single-center (Maastricht), double-blind, randomized, placebo-controlled crossover design Key comparisons: – Intermezzo® 3.5mg vs. placebo, dosed 4 hours prior to driving – In

  21. Slide 21: Intermezzo highway driving study results

    Intermezzo ® highway driving study results 4 hrs after MOTN Intermezzo® dosing – Test condition consistent with proposed label – Primary analysis (symmetry): no statistically significant effect – Secondary analysis (mean): statistically significant but small effect of 0.8 cm SDLP 3 hrs after MOTN In

  22. Slide 22: Effect on driving by various hypnotics and blood alcohol concentrations

    Effect on driving produced by various hypnotics and blood alcohol concentrations: cross study comparison Zopiclone and US-marketed hypnotics Brookhuis K. Hum. Psychopharmacol. Clin. Exp. 1998;13:S64–S69. 8 10-11h 10-11h post-dose 7 post-dose 10-11h 6 post-dose Intermezzo® DUI blood highway driving s

  23. Slide 23: Intermezzo: intellectual property

    * * * * * * * * * * Intermezzo®: intellectual property

  24. Slide 24: Two formulation patents issued; method of use patents pending

    Intermezzo ®: two formulation patents issued; method of use patents pending Formulation for transmucosal absorption – Two issued U.S. patents - 7,682,628 and 7,658,945 – Patents expire no sooner than February 2025 – Low dose zolpidem, ~1mg to ~5mg – Formulation with buffer system for transmucosal ab

  25. Slide 25: Setrodon

    * * * * * * * * * * Setrodon™ (ultra low dose ondansetron) Adjunctive therapy in patients with obsessive compulsive disorder not adequately responsive to SSRI treatment 25

  26. Slide 26: Significant unmet need: OCD patients not responding to SSRI treatment

    Significant unmet medical need: OCD patients not responding adequately to SSRI treatment Obsessive Compulsive Disorder – Intrusive thoughts and repetitive actions to reduce distress – Affects 1% to 2% of U.S. adult population, 40% to 50% seek treatment – Significantly impacts everyday life activitie

  27. Slide 27: Pilot studies: ultra low dose adjunctive ondansetron in SSRI resistant OCD

    Pilot studies: ultra low dose adjunctive ondansetron therapy in SSRI resistant OCD Ondansetron (5-HT3 antagonist approved as Zofran®) – Affects serotonin and dopamine pathways – Typical daily Zofran® doses of 16 mg to 24 mg for chemotherapy- induced nausea and vomiting Two 12 week open-label adjunct

  28. Slide 28: Improvement measured as % decrease on YBOCS

    Improvement: measured as a % decrease over baseline on the Yale Brown Obsessive Compulsive Scale (YBOCS) Pilot Study B, n=21 0% 0% 10% 10% 20% 20% 30% 30% 40% 40% Responders All patients Non-responders 50% 50% Week Week Week Week Week Week Week Week Week Week Week Week 2 4 6 8 10 12 2 4 6 8 10 12 Al

  29. Slide 29: Relapse following discontinuation in responders

    Relapse following discontinuation in responders Pilot Study B, n=12 of 21 (responders only) 40 Phase 1 Phase 2 Ondansetron augmentation Discontinuation 30 38.3% YBOCS worsening 20 from Week 12 10 Week Week Week Week Week Week Week Week Week 0 2 4 6 8 10 12 14 16 29

  30. Slide 30: Setrodon: development overview

    Setrodon™: development overview 505b2 NDA pathway Phase 2 study, n 150 – To start Q1 2011, top-line results 2012 – Approx. $10M investment through end of Phase 2 study Intellectual property – Method of use patent application filed, priority date May 19, 2009 – Ondansetron, up to ~1.5 mg/day – Pendin

  31. Slide 31: Financial overview

    * * * * * * * * * * Financial overview

  32. Slide 32: Financial position: September 30, 2010

    Financial position: September 30, 2010 Cash & investments: $74.2 M Q3 2010 cash burn rate: $ 1.6 M / month Shares outstanding: 13.4 M Options / warrants / other: 2.5 Total: 15.9 M Employees: 31 32

  33. Slide 33: Key Transcept activities and goals

    Key Transcept activities and goals Completed Intermezzo ® US marketing partnership, July 09 Patent coverage: two Intermezzo ® formulation patents issued Highway driving study data, Oct 2010 Intermezzo® NDA submitted Jan 2011 Intermezzo® pre-launch planning Intermezzo® PDUFA date Jul 2011 (estimate)

  34. Slide 34: Trademark notices

    Intermezzo ® is a registered trademark of Transcept Pharmaceuticals, Inc. Ambien ® and Ambien CR ® are registered trademarks of sanofi-aventis Lunesta is a registered trademark of Sunovion Pharmaceuticals Inc. Zofran ® and Paxil ® are registered trademarks of The GlaxoSmithKline Group of Companies P

Transcept Pharmaceuticals — Investor Presentation (January 2011) on 6ix